skip to main content


Title: HYPO/HYPERGLYCEMIC CONSTRAINED DESIGN OF IV INSULIN CONTROL FOR TYPE 1 DIABETIC PATIENTS WITH MEAL AND INITIAL CONDITION UNCERTAINTIES USING SEQUENTIAL QUADRATIC PROGRAMMING
The focus of this paper is on the development of an open loop controller for type 1 diabetic patients which is robust to meal and initial condition uncertainties in the presence of hypoand hyperglycemic constraints. Bernstein polynomials are used to parametrize the evolving uncertain blood-glucose. The unique bounding properties of these polynomials are then used to enforce the desired glycemic constraints. A convex optimization problem is posed in the perturbation space of the model and is solved repeatedly to sequentially converge on a sub-optimal solution. The proposed approach is demonstrated on the classic Bergman model for Type 1 diabetic patients.  more » « less
Award ID(s):
1537210
NSF-PAR ID:
10113130
Author(s) / Creator(s):
;
Date Published:
Journal Name:
ASME 2018 International Mechanical Engineering Congress and Exposition.
Format(s):
Medium: X
Sponsoring Org:
National Science Foundation
More Like this
  1. The focus of this paper is on the development of a chance constrained controller for type 1 diabetic patients in the presence of model, meal and initial condition uncertainty. Since the chance constraints require the mean and variance of the evolving uncertain blood-glucose, a conjugate unscented transform based approach is used to estimate the blood-glucose statistics. The proposed approach is demonstrated on the classic Bergman model augmented with a gut dynamics model. 
    more » « less
  2. Abstract

    Type 1 diabetes mellitus (T1DM) is an autoimmune disease characterized by insulin deficiency, and patients with diabetes have an increased risk of bone fracture and significantly impaired fracture healing. Proinflammatory cytokine tumor necrosis factor‐alpha is significantly upregulated in diabetic fractures and is believed to underlie delayed fracture healing commonly observed in diabetes. Our previous genetic screen for the binding partners of progranulin (PGRN), a growth factor‐like molecule that induces chondrogenesis, led to the identification of tumor necrosis factor receptors (TNFRs) as the PGRN‐binding receptors. In this study, we employed severalin vivomodels to ascertain whether PGRN has therapeutic effects in diabetic fracture healing. Here, we report that deletion of PGRN significantly delayed bone fracture healing and aggravated inflammation in the fracture models of mice with T1DM. In contrast, recombinant PGRN effectively promoted diabetic fracture healing by inhibiting inflammation and enhancing chondrogenesis. In addition, both TNFR1 proinflammatory and TNFR2 anti‐inflammatory signaling pathways are involved in PGRN‐stimulated diabetic fracture healing. Collectively, these findings illuminate a novel understanding concerning the role of PGRN in diabetic fracture healing and may have an application in the development of novel therapeutic intervention strategies for diabetic and other types of impaired fracture healing.

     
    more » « less
  3. Abstract

    Impaired wound healing is a common complication for diabetic patients and effective diabetic wound management remains a clinical challenge. Furthermore, a significant problem that contributes to patient morbidity is the suboptimal quality of healed skin, which often leads to reoccurring chronic skin wounds. Herein, a novel compound and biomaterial building block, panthenol citrate (PC), is developed. It has interesting fluorescence and absorbance properties, and it is shown that PC can be used in soluble form as a wash solution and as a hydrogel dressing to address impaired wound healing in diabetes. PC exhibits antioxidant, antibacterial, anti‐inflammatory, and pro‐angiogenic properties, and promotes keratinocyte and dermal fibroblast migration and proliferation. When applied in a splinted excisional wound diabetic rodent model, PC improves re‐epithelialization, granulation tissue formation, and neovascularization. It also reduces inflammation and oxidative stress in the wound environment. Most importantly, it improves the regenerated tissue quality with enhanced mechanical strength and electrical properties. Therefore, PC could potentially improve wound care management for diabetic patients and play a beneficial role in other tissue regeneration applications.

     
    more » « less
  4. Geographically-based screening policies for diabetic retinopathy (DR) can be effective in developing teleretinal imaging (TRI) guidelines while identifying patients with limited geographic access to eye care. This study conducts cost-effectiveness analysis of different screening policies for urban and rural diabetic patients in Western Pennsylvania. A Monte Carlo simulation model was used to evaluate the cost-effectiveness of 2 standardized screening policies (annual clinic-based screening (ACS) and annual TRI-based screening (ATRI)) and a personalized TRI-based screening policy (PTRI) for both urban and rural cohorts. PTRI was generated by a previously developed mathematical model that autonomously makes semi-annual screening recommendations based on each patient’s disease progression and compliance (Dorali et al. IOVS 2022; 63(7)). For each policy, hypothetical urban and rural cohorts of 50,000 patients were simulated and lifetime QALYs and costs were collected for each patient. TRI compliance rates were derived from electronic medical records. Compliance with clinic-based screening was selected from literature-based values (12-45% for rural patients and 50-65% for urban patients). For a base case urban cohort with an A1C level of 7% and entering age of 40, costs per QALY gain (CPQ) for ACS, ATRI, and PTRI were $744.93±1.57, $792.38±1.64, and $714.60±1.56, respectively; PTRI produced more cost saving than ACS with the same QALY gain (See Fig 1). For a base case rural cohort, CPQ for ACS, ATRI, and PTRI were $869.15±1.80, $819.24±1.88, and $761.51±1.42, respectively; both ATRI and PTRI dominated ACS in QALY gains and cost saving (Fig 1). PTRI recommended TRI more to rural patients (94.13±0.01%) than to urban patients (87.20±0.02%). For the rural cohort, the minimum average TRI compliance rate such that ATRI is more cost-effective than ACS was 56% (Fig 2). TRI-based screening was found more beneficial for rural patients. PTRI was found dominant in QALY gain and cost saving for both urban and rural cohorts against standardized policies. These findings suggest that TRI is best utilized when location-specific factors such as geographic access to care or TRI compliance are considered. 
    more » « less
  5. null (Ed.)
    Abstract Skeletal muscle is a tissue that is directly involved in the progression and persistence of type 2 diabetes (T2D), a disease that is becoming increasingly common. Gaining better insight into the mechanisms that are affecting skeletal muscle dysfunction in the context of T2D has the potential to lead to novel treatments for a large number of patients. Through its ability to emulate skeletal muscle architecture while also incorporating aspects of disease, tissue-engineered skeletal muscle (TE-SkM) has the potential to provide a means for rapid high-throughput discovery of therapies to treat skeletal muscle dysfunction, to include that which occurs with T2D. Muscle precursor cells isolated from lean or obese male Zucker diabetic fatty rats were used to generate TE-SkM constructs. Some constructs were treated with adipogenic induction media to accentuate the presence of adipocytes that is a characteristic feature of T2D skeletal muscle. The maturity (compaction and creatine kinase activity), mechanical integrity (Young's modulus), organization (myotube orientation), and metabolic capacity (insulin-stimulated glucose uptake) were all reduced by diabetes. Treating constructs with adipogenic induction media increased the quantity of lipid within the diabetic TE-SkM constructs, and caused changes in construct compaction, cell orientation, and insulin-stimulated glucose uptake in both lean and diabetic samples. Collectively, the findings herein suggest that the recapitulation of structural and metabolic aspects of T2D can be accomplished by engineering skeletal muscle in vitro. Impact Statement The tissue engineering of skeletal muscle to model disease and injury has great promise to provide a tool to develop and/or improve therapeutic approaches for improved health care. A tissue-engineered skeletal muscle model of one of the most common and debilitating diseases, type 2 diabetes, has been developed in vitro as evidenced by the structural and metabolic alterations that are consistent with the disease phenotype in vivo. 
    more » « less